ADC Therapeutics
ADC Therapeutics is a Swiss-listed biopharmaceutical company (NYSE: ADCT) that develops antibody drug conjugates using proprietary PBD technology, commercializing ZYNLONTA for relapsed/refractory diffuse large B-cell lymphoma and expanding into earlier lines and combinations.
- Company typePublic
- Founded2011
- HeadquartersLausanne, Switzerland
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What ADC Therapeutics does
ADC Therapeutics SA is a Swiss-domiciled, commercial-stage biopharmaceutical company founded in 2011 and listed on the NYSE (ticker: ADCT), focused on the development of antibody drug conjugates (ADCs) using a proprietary pyrrolobenzodiazepine (PBD) dimer payload platform. Its lead and only commercial product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC that received FDA accelerated approval in April 2021 and European Commission conditional approval in the same year for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic therapies. ADC Therapeutics generates substantially all of its revenue from U.S. ZYNLONTA product sales (FY2025 net product revenue of $73.6 million), with the company headquartered in Epalinges, Switzerland and operating a U.S. subsidiary in New Providence, New Jersey.
The company is pursuing label expansion through two principal clinical trials: the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab versus R-GemOx in second-line DLBCL (which met its PFS primary endpoint with reported safety signals including 27 patient deaths in the treatment arm), and the Phase 1b LOTIS-7 trial combining ZYNLONTA with Roche's CD20xCD3 bispecific glofitamab, which reported 90% overall response and 78% complete response rates. Beyond ZYNLONTA, the disclosed pipeline consists of a next-generation PSMA-targeting exatecan-based ADC (ADCT-601) in IND-enabling activities, with earlier programs ADCT-212 and ADCT-701 discontinued. Distribution is handled through specialty pharmacies supported by an Advancing Patient Support portal, with commercial engagement driven by a focused sales force and medical affairs team targeting oncologists and hematologists.
The business model is a single-asset, product-sales biopharmaceutical model funded by repeated equity raises (~$265M across 2024-2025) and a $300M HealthCare Royalty financing agreement amended in February 2026 to reduce the change-of-control obligation from $750M to $150M. The company reported a $142.6M FY2025 net loss and announced a 17% workforce reduction in June 2026 to deliver approximately $10M in annualized savings, with management guiding to a potential ZYNLONTA relaunch in 2027 once LOTIS-5/7 readouts are absorbed. Cash and cash equivalents stood at $261.3M at year-end 2025 and $231.0M at end of Q1 2026, supporting an operating runway into 2028.
ADC Therapeutics firmographics
Firmographics- Name
- ADC Therapeutics
- Legal name
- ADC Therapeutics SA
- Website
- https://adctherapeutics.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- ADC Therapeutics is a Swiss-listed biopharmaceutical company (NYSE: ADCT) that develops antibody drug conjugates using proprietary PBD technology, commercializing ZYNLONTA for relapsed/refractory diffuse large B-cell lymphoma and expanding into earlier lines and combinations.
- Ownership category
- akta.pro rank
ADC Therapeutics industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where ADC Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
ADC Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- ZYNLONTA Product Sales: Commercial-stage biopharmaceutical company generating revenue from sales of ZYNLONTA (loncastuximab tesirine-lpyl), its FDA-approved antibody drug conjugate for treatment of relapsed or refractory diffuse large B-cell lymphoma. Q4 2025 net product revenue of $22.3 million, full-year 2025 revenue of $73.6 million.
- PIPE Financings: Private placement investments including $60 million PIPE financing (October 2025) and $100 million private placement (June 2025) to support clinical development and commercialization.
- Royalty Financing: HealthCare Royalty financing agreement amended to reduce change of control payment obligation in exchange for warrants. Original agreement involved $300 million in funding.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | ZYNLONTA is a prescription medicine |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
ADC Therapeutics product offering
Product offeringCore offering
ADC Therapeutics is a commercial-stage biopharmaceutical company that develops antibody drug conjugates (ADCs) using proprietary pyrrolobenzodiazepine (PBD) dimer warhead technology. Its approved and commercialized product is ZYNLONTA (loncastuximab tesirine-lpyl), an FDA- and European Commission-approved CD19-directed ADC for adults with relapsed or refractory diffuse large B-cell lymphoma after two or more prior systemic therapies. Revenue is generated primarily through ZYNLONTA product sales via specialty pharmacy distribution.
Product overview
ADC Therapeutics is a commercial-stage biopharmaceutical company focused on antibody drug conjugates (ADCs) with proprietary PBD (pyrrolobenzodiazepine) warhead technology. The company's lead product is ZYNLONTA (loncastuximab tesirine-lpyl), an FDA-approved CD19-directed ADC for relapsed/refractory DLBCL. The company is expanding ZYNLONTA into earlier lines of therapy and indolent lymphomas through multiple clinical trials including LOTIS-5 (Phase 3) and LOTIS-7 (Phase 1b combination with glofitamab). The pipeline also includes a next-generation PSMA-targeting exatecan-based ADC in development, while discontinued programs include ADCT-212 and ADCT-701. ADC Therapeutics operates with strategic collaborations for co-development and academic partnerships in ADC research.
Differentiator
Problem solved
Functional benefit
Brands
- ZYNLONTA: CD19-directed antibody drug conjugate (ADC) using pyrrolobenzodiazepine (PBD) technology, approved for relapsed or refractory diffuse large B-cell lymphoma
- PBD Technology
Products and services
- ZYNLONTA (loncastuximab tesirine-lpyl) FDA- and European Commission-approved CD19-directed antibody drug conjugate (ADC) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic therapies. It uses proprietary pyrrolobenzodiazepine (PBD) dimer warhead technology to deliver a potent cytotoxic payload directly to CD19-expressing tumor cells. Prescribed by hematologists and oncologists and distributed through specialty pharmacies, with patient access supported via the Advancing Patient Support program.
- ADC Therapeutics Partnering Programs Strategic collaborations offering industry partners access to ADC Therapeutics' proprietary PBD technology platform for co-development of antibody drug conjugates, as well as research collaborations with academic and industry scientists on novel ADC technologies. Includes co-development, research collaboration, and academic study partnerships across the ADC field.
Quantifiable outcome
- Phase 3 LOTIS-5 met primary endpoint of progression-free survival (HR=0.73; p=0.008) with median PFS of 6.1 months vs 4.7 months for R-GemOx regimen
- +3 more outcomes
Companies that use ADC Therapeutics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
ADC Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ADC Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Roche (Glofitamab/Columvi)coreLOTIS-7 Phase 1b trial evaluates ZYNLONTA in combination with Roche's glofitamab (COLUMVI) bispecific antibody for relapsed or refractory B-cell non-Hodgkin lymphoma. Demonstrated 90% overall response rate and 78% complete response rate in clinical trials.
Scale indicators13 records
Recent moves6 records
Expansion highlights4 records
ADC Therapeutics competitors and assessment
Company assessmentDirect peers
- ImmunoGen (AbbVie subsidiary): Direct ADC competitor acquired by AbbVie in 2024 for $10.1B; developed ELAHERE, an FDA-approved ADC for ovarian cancer. Highly comparable as a similarly-sized, single-product commercial-stage ADC company with a linker-payload platform.
- Seagen (Pfizer subsidiary): Leading commercial ADC company acquired by Pfizer for $43B; developed Adcetris, Padcev, Tukysa, and Tivdak. Direct comparator given its ADC technology platform and hematologic/oncology focus.
- Daiichi Sankyo: Japanese pharmaceutical leader in ADC technology with DXd payload platform; developed Enhertu and Datroway in partnership with AstraZeneca. Most relevant peer for ADC platform monetization and pipeline depth.
- Takeda Pharmaceutical: Develops and markets Adcetris (with Seagen) for lymphoma; has broad ADC ambitions. Direct comparator in hematologic cancer ADCs with global commercial reach.
- Genmab: Develops bispecific antibodies (epcoritamab/talquetamab) in DLBCL; competes in the same indication as ZYNLONTA via different modality. Emerging player with overlapping hematology-oncology focus.
Broad incumbents
- AstraZeneca: Global oncology leader and ADC partner via Enhertu/Datroway collaboration with Daiichi Sankyo; has AstraZeneca board representation at ADC Therapeutics (Tyrell Rivers). Broad incumbent with overlapping ADC ambitions.
- Roche: Strategic partner via LOTIS-7 combination with glofitamab (COLUMVI); also a leading oncology incumbent with bispecific antibodies and CAR-T pipelines (Lunsumio, Tecartus) that compete in DLBCL.
- Pfizer: Acquired Seagen for $43B to build ADC franchise; operates oncology portfolio including CAR-Ts and ADCs that overlap with ADC Therapeutics' hematologic oncology focus. Provides read-through to strategic value of ADC platforms.
- AbbVie: Acquired ImmunoGen and its ADC franchise; major oncology incumbent. Provides strategic-acquirer comparable for ADC Therapeutics given its single-product commercial profile.
- Bristol Myers Squibb: Major oncology incumbent with Breyanzi (lisocabtagene maraleucel) CAR-T for DLBCL and a broad hematology pipeline; competes with ZYNLONTA in r/r DLBCL and serves as a benchmark large-pharma oncology franchise.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
ADC Therapeutics social profiles
Digital presenceADC Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ADC Therapeutics leadership team
Management profileNumber of profiles
Profiles15 records
ADC Therapeutics funding detail
Funding detailFunding overview
Funding rounds13 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ADC Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ADC Therapeutics
What does ADC Therapeutics do?
ADC Therapeutics is a commercial-stage biopharmaceutical company that develops antibody drug conjugates (ADCs) using proprietary pyrrolobenzodiazepine (PBD) dimer warhead technology. Its approved and commercialized product is ZYNLONTA (loncastuximab tesirine-lpyl), an FDA- and European Commission-approved CD19-directed ADC for adults with relapsed or refractory diffuse large B-cell lymphoma after two or more prior systemic therapies. Revenue is generated primarily through ZYNLONTA product sales via specialty pharmacy distribution.
Is ADC Therapeutics a public or private company?
ADC Therapeutics is a public company. It is classified as public and is currently operating.
When was ADC Therapeutics founded?
ADC Therapeutics was founded in 2011. It employs 251 to 500 people.
Where is ADC Therapeutics based?
ADC Therapeutics is headquartered in Lausanne, Switzerland, in the Europe region.
How does ADC Therapeutics make money?
Three revenue lines are on record. ZYNLONTA Product Sales are the primary driver. The others are PIPE Financings and royalty Financing.
Who are ADC Therapeutics's main competitors?
Direct peers on record are ImmunoGen (AbbVie subsidiary), Seagen (Pfizer subsidiary), Daiichi Sankyo, Takeda Pharmaceutical and Genmab. Broad incumbents are AstraZeneca, Roche, Pfizer, AbbVie and Bristol Myers Squibb.
Does ADC Therapeutics have an API?
No public API is recorded for ADC Therapeutics.
What industry is ADC Therapeutics in?
ADC Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 325414 and its SIC code is 2834.